Menu
Recruiting NCT06012097

Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease

Phase IV Interventional De Quervain Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Diclofenac gel, Aromatherapy gel.
Who it may be relevant to
Registry conditions: De Quervain Disease. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease : Monocentric Study, Controlled, Randomized, Partially Blinded, in Paralleled Groups

Overview

De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. This pathology is recognized as a musculoskeletal disorder of the upper limb triggering functional deficits resulting to possible modifications in the professional activity, sources of absenteeism, thus constituting an economic cost for society. At the etiological level, this pathology also affects young mothers (it's called "mother's wrist" or mommy thumb"), mobile phone users ("textonite", "Blackberryte") or video game players ("Nintendoite"). Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. Howewer, these therapies have undesirable effects. The interest of this study is therefore to propose another therapy based on aromatherapy gel.

Interventions

  • Drug Diclofenac gel
    using diclofenac as a comparator
  • Drug Aromatherapy gel
    using Aromatherapy gel as an experimetnal treatment

Primary outcome measures

  • Measure of pain during the WHAT test [Time frame: Day 0]
  • Measure of pain during the WHAT test [Time frame: Day 42]
  • Measure of pain during the WHAT test [Time frame: Day 84]

Eligibility criteria

Inclusion criteria

  • Male or female patient aged 18 to 75,
  • Patient with unilateral De Quervain's tenosynovitis,
  • Patient cared in the Hand Surgery Department, SOS Mains Emergency Department or Rheumatology Department of Strasbourg University Hospitals,
  • Patient informed of the results of the prior medical examination,
  • Informed consent signed by the patient,
  • Patient affiliated to a health insurance social protection scheme or beneficiary,
  • For a woman of childbearing potential, negative urine pregnancy test at the inclusion visit and maintenance of effective contraception throughout the study.

Exclusion criteria

  • Pregnant or breastfeeding patient,
  • Patient allergic to a component of the gel with essential oils, Dicloflenac®, NSAIDs, or one of the excipients
  • Patient treated with oral non-steroidal anti-inflammatory drugs
  • Patient with ongoing treatment with another ointment at the treatment application site (radial edge of the wrist)
  • Patient with damaged skin, whatever the lesion: oozing dermatosis, eczema, infected lesion, burn or wound,
  • Patient with atopic skin disease,
  • Patient with epilepsy or with a history of epilepsy,
  • Patient with a history of homolateral De Quervain's tenosynovitis, or having already had corticosteroid infiltrations in the 6 months before his inclusion on the ipsilateral side of the pathology,
  • Patient with associated tendinopathies in the elbow or forearm region,
  • Impossibility of giving the patient information (patient in an emergency situation, patient with difficulties of understandin, agitation of the patient),
  • Patient under legal protection, under guardianship or curatorship.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

France · 1 center
  • Service SOS Main — Strasbourg

Identifiers

NCT: NCT06012097 · 7452

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗